| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
When it comes to cancer, there’s innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all got acquainted with during the COVID-19 era as it allowed pharmaceutical companies like Pfizer Inc (NYSE:PFE) and Moderna Inc (NASDAQ:MRNA) to develop their groundbreaking vaccines in record time. By the looks of it, this was only the beginning of the healthcare revolution that mRNA triggered.
Mainz Biomed N.V. (NASDAQ:MYNZ) to revolutionize colorectal cancer diagnostics and prevention.
CRC has been recognized as the second most lethal cancer both in the U.S. and Europe. However, it is also among the most preventable ones as early detection results in survival rates above 90%.
A company specialized in molecular genetics diagnostic, Mainz Biomed, whose flagship product, ColoAlert®, a CRC screening test already showed its ability to detect even pre-cancerous polyps known as advanced adenomas thanks to mRNA biomarkers, just announced significant findings from a pooled clinical study as its flagship project undergoes a pivotal FDA clinical study for U.S. regulatory approval.
Mainz Biomed conducted this study to fine tune and evaluate novel mRNA biomarkers along with proprietary AI algorithm for integration into pivotal FDA PMA clinical trial for its next-generation CRC screening tool.
By analyzing 690 subjects, including new patients from Mainz Biomed's ColoFuture and eAArly DETECT trials across 30 clinical sites in the U.S. and Europe, Mainz reported topline results that confirm the positive results it had previously reported. The study's topline results showcased a sensitivity of 92% and a specificity of 90% for CRC detection, as well as an 82% sensitivity for advanced adenoma. Mainz Biomed conducted the evaluations by using its novel mRNA biomarkers, a fecal immunochemical test (FIT), and a proprietary AI algorithm. When announcing the results, Mainz Biomed CEO Guido Baechler announced these results mark a critical milestone towards the company’s FDA PMA pivotal study, ReconAAsense. Mainz Biomed plans to report the findings of the study at a major medical conference during the second quarter of 2024.
With the help of mRNA, promising new treatments have emerged.
With the power to detect a pre-cancerous stage, Mainz Biomed is able to revolutionize the CRC diagnostics field. With the power of a mRNA cancer vaccine that Moderna developed with Merck, patients’ bodies could get a personalized instruction on how to fight cancer, targeting and destroying only cancer cells. Therefore, the potential of mRNA in fighting cancer cannot be overstated as mRNA promises to revolutionize both cancer diagnostics and treatment.
Moderna and OpenAI to exploit AI’s potential to advance mRNA medicine.
Since its beginnings, Moderna has leveraged the power of machine learning and its is the first of its peers to embrace the digital world since its inception. It embarked on a venture with OpenAI early last year, with the launch of a customized version of ChatGPT, mChat. Purpose built GPTs are now an integral part of its business units. On Wednesday, Moderna announced the deepening of the partnership to advance the future of mRNA medicine.
By the looks of it, mRNA promises a new era for healthcare.
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.
